Nephrology (Renal Anemia and Bone and Mineral Metabolism) | TreatmentTrends | US | Q1 2014
This quarterly report provides a detailed analysis of emerging and current therapies in nephrology based on responses from surveyed U.S. nephrologists. Emphasis is on anemia management (ESAs and IV Iron), calciumphosphorus metabolism (phosphate binders) and secondary hyperparathyroidism (vitamin D and calcimimetic agents). Covers the management of dialysis and mid-late stage CKD patients.
Topics include percent of patients on each therapy, patient share, therapy initiation levels, perception of current laboratory values, attribute importance and performance ratings, impact of dialysis bundling, compliance, statement agreements and reaction to new products in development, among other topics.
Related Market Assessment Reports
Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)
The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…
Report
Diabetic Macular Edema / Diabetic Retinopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Macular Edema (US)
Diabetic macular edema (DME) is a serious complication of diabetic retinopathy caused by persistently elevated blood glucose levels. Without timely treatment, DME can progress to significant vision…
Report
Multiple System Atrophy – Unmet Need – Multiple System Atrophy (US/EU) – Unmet Need – Multiple System Atrophy (US/EU)
Multiple system atrophy (MSA) is a rare, rapidly progressing neurodegenerative synucleinopathy that disrupts movement, balance, and autonomic function. Current management comprises only symptomatic…
